Yang J, Liu Y, Liu S. Comment on “Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression”. World J Gastrointest Oncol 2023; 15(2): 368-371 [PMID: 36908318 DOI: 10.4251/wjgo.v15.i2.368]
Corresponding Author of This Article
Shi Liu, PhD, Chief Physician, Central Laboratory, the Third Affiliated Hospital, Qiqihar Medical University, No. 27 Taishun Street, Tiefeng District, Qiqihar 161000, Heilongjiang Province, China. shiliu2199@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Feb 15, 2023; 15(2): 368-371 Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.368
Comment on “Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression”
Jian Yang, Ying Liu, Shi Liu
Jian Yang, Shi Liu, Central Laboratory, The Third Affiliated Hospital, Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China
Ying Liu, Department of Medical Oncology, The Third Affiliated Hospital, Qiqihar Medical University, Qiqihar 161000, Heilongjiang Province, China
Author contributions: Yang J designed and wrote this report; Liu S gave guidance on article revision; Liu Y reviewed the literature and contributed to drafting the manuscript; all authors issued final approval for the version to be submitted.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shi Liu, PhD, Chief Physician, Central Laboratory, the Third Affiliated Hospital, Qiqihar Medical University, No. 27 Taishun Street, Tiefeng District, Qiqihar 161000, Heilongjiang Province, China. shiliu2199@163.com
Received: November 19, 2022 Peer-review started: November 19, 2022 First decision: December 25, 2022 Revised: January 3, 2023 Accepted: February 2, 2023 Article in press: February 2, 2023 Published online: February 15, 2023 Processing time: 87 Days and 13.3 Hours
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has become a global burden, further exacerbating the occurrence of risk events in cancer patients. The high risk of death from pancreatic cancer makes it one of the most lethal malignancies. Recently, it was reported in the World Journal of Gastrointestinal Oncology that COVID-19 influences pancreatic cancer progression via the lung–gut–pancreatic axis, and the authors provided insights into the intrinsic crosstalk mechanisms in which the gut microbiota is involved, the characteristics and effects of inflammatory factors, and immunotherapeutic strategies for treating both diseases. Here, we review the latest cutting-edge researches in the field of the lung-gut-pancreatic axis and discuss future perspectives to address the severe survival challenges posed by the COVID-19 pandemic in patients with pancreatic cancer.
Core Tip: The coronavirus disease 2019 (COVID-19) pandemic has become a global burden, further exacerbating the occurrence of mortality risk events in patients with pancreatic cancer. The aim of this new article is to highlight the need for lung-gut-pancreatic axis-based studies with a focus on intra-axis microbiota crosstalk and potential mechanisms of association to address the severe survival challenges posed by the COVID-19 pandemic in patients with pancreatic cancer.
